An interventional study of 689 nm Laser Treatment of the Macula and Half Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy, sponsored by Università degli Studi di Brescia. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-15.
Sponsored by Università degli Studi di Brescia · Not applicable, Interventional, and Treatment
Acute central serous chorioretinopathy (CSC) is a common disorder in middle-aged patients, characterized by serous retinal detachment in the macular region. We evaluated half-dose verteporfin photodynamic therapy (hd-PDT) versus 689 nm laser treatment in chronic CSC.
Twenty-two eyes of 22 patients with symptomatic chronic CSC were randomized in a 1:1 ratio to receive hd-PDT (group 1) or 689-LT delivering 95 J/cm2 by application of an intensity of 805 mW/cm2 over 118 seconds. Best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography findings were compared between groups.
86 studies on the registry are indexed under Central Serous Chorioretinopathy; 13 are open to participants now.
This study's planned enrollment of 22 is below the median of 30 across 62 interventional studies indexed under Central Serous Chorioretinopathy.
Browse Central Serous Chorioretinopathy studies →Università degli Studi di Brescia is the lead sponsor of 46 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Half Dose Photodynamic Therapy The safety enhanced PDT protocol for CSC was performed using half the normal dose of verteporfin (Visudyne, Novartis Pharma, Switzerland), which is 3 mg/m2 verteporfin
Procedure: Half Dose Photodynamic Therapy
A 689 nm laser treatment delivering 95 J/cm2 by application of an intensity of 805 mW/cm2 over 118 seconds was performed. No verteporfin or other drugs were administered to the patients.
Procedure: 689 nm Laser Treatment of the Macula
Best-corrected Visual Acuity (LogMAR)
Measured with ETDRS chart
Time frame: 6 months
Central Retinal Thickness (micron)
Measured with OCT
Time frame: 6 months
Subfoveal Choroidal Thickness (micron)
Measured with OCT
Time frame: 6 months
Ellipsoid Zone Recovery (integrity of IS/OS line)
As visible with OCT scans
Time frame: 6 months
No study locations are listed for this record.
This study is status unknown, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Serous Chorioretinopathy→
Università degli Studi di Brescia